Potent, selective and orally available NLRP3 inflammasome inhibitor. Blocks the release of IL-1beta in macrophages primed with LPS and activated with ATP or nigericin, but it does not inhibit NLRP1, NLRC4, AIM2, TLR2 signaling or priming of NLRP3. Prevents oligomerization of ASC in cells stimulated with LPS and nigericin. Active in vivo, blocking the production of IL-1beta and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome (CAPS). Also active in ex vivo samples from individuals with Muckle-Wells syndrome. Potential therapeutic agent for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases.
Solubility & Handling
Storage instructions
+4°C
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.
Understanding purity and quality - a guide for life scientists